WO2000069868A1 - Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues - Google Patents
Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues Download PDFInfo
- Publication number
- WO2000069868A1 WO2000069868A1 PCT/JP2000/003055 JP0003055W WO0069868A1 WO 2000069868 A1 WO2000069868 A1 WO 2000069868A1 JP 0003055 W JP0003055 W JP 0003055W WO 0069868 A1 WO0069868 A1 WO 0069868A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- general formula
- formula
- added
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to analogs of physiologically active substances, analogs thereof, and methods for producing them.
- the compound of the present invention has a dipeptidyl peptidase IV inhibitory activity, and is used, for example, as a physiologic agent used as an immunomodulator, a hormone modulator, an anti-HIV drug, an anti-allergic drug, an anti-inflammatory drug, an anti-rheumatic drug, or the like. Expected as an active substance.
- dipeptidyl peptidase IV present on the surface of T cells is involved in T cell activation (Immunol. To day, 15, 180–184 (1994)). Plays an important role in the immune system. Also, dipeptidyl peptidase IV is involved in the degradation of growth hormone-releasing hormone in serum (J. Clin. Invest., 83, 1533-1540 (1899)). Hitherto, as a physiologically active substance having a dipeptidyl peptidase IV inhibitory activity, diprotin ⁇ and ⁇ (J. Antibiotics, 37, 422-425 (1 984)) and the like are known.
- the present inventors have previously found sulfostine as such a physiologically active substance, and as a method for producing the same, cultured in a medium a microorganism belonging to the genus Streptomyces and having the ability to produce the physiologically active substance sulfostin. Then, a method was developed in which a physiologically active substance, sulfostine, was produced and accumulated in the culture, and collected therefrom (patent application No. 1997-17221).
- sulfostin has a strong inhibitory effect on the enzyme, its productivity is not necessarily high if it is produced by a method of collecting it from microbial cultures, and it is not suitable for mass production.
- the present inventors have sufficiently elucidated the chemical structure of the physiologically active substance sulfostin, and found that it can be produced by synthetic chemical means.
- sulfostine stereoisomers and analogs which do not exist in nature can be produced by the same synthetic chemical means, and these also exhibit strong enzyme inhibitory activity like sulfostine.
- the present invention has been completed based on the above findings.
- the present invention provides a compound represented by the general formula (I V ′)
- n is an integer of 0 3 except for the case where n is 2, the configuration of C is S and the configuration of P ⁇ is R)
- n represents an integer of 03, and Z represents a protecting group for an amino group
- n and Z are as described above, and M represents a monovalent cation.
- t invention further relates to a method of manufacturing analogs of the general formula (I)
- n represents an integer of 0 to 3
- Z represents a protecting group for an amino group
- the present inventors have elucidated by various spectrographs that the chemical structure of sulfostin has a structure represented by the following formula (V). Also, because of the hydrolysis experiment, L-orditin was obtained, so the configuration of the base of the amino group was S. Revealed.
- L-Orditin was esterified and ring-closed to give L-orditin lactam, which was protected with an amino group by a conventional method to give a compound of the general formula (VI).
- z is a commonly used protecting group for an amino group, for example, a benzyloxycarbonyl group (a benzyl group may be substituted with a lower alkyl group, a lower alkoxy group, an acyloxy group, a nitro group, a halogen, etc.), t-butoxycarbonyl group and other protecting groups, such as formyl, acetyl, trifluoroacetyl and the like; amide-type protecting groups such as phthaloyl; and preferably carbamate-type protecting groups. And more preferably a benzyloxycarbonyl group.
- the compound is reacted with POX 3 (X is a leaving group such as halogen or imidazole, preferably chlorine), and further reacted with ammonia to obtain a compound of the general formula (VII).
- X is a leaving group such as halogen or imidazole, preferably chlorine
- Z is the same amino group-protecting group as in the general formula (VI).
- the solvent is a non-protonic solvent and may be any solvent that dissolves the compound of the general formula (VI), but is preferably an ether solvent such as THF.
- the base any base such as butyllithium, sodium hydride, lithium hydride, potassium hydride, sodium bistrimethylsilylamide, and lithium bistrimethylsilylamide can be used as long as it can replace the hydrogen of the lactam with a metal. is there.
- the reaction is carried out at a temperature between 80 ° C and 100 ° C, preferably at a temperature between 180 ° C and 0 ° C-
- the compound of the general formula (VII) is mixed with sulfur trioxide or a complex thereof, for example, a pyridine complex, a DMF complex, a trimethylamine complex in a non-aqueous solvent at 0 to 100 ° C, preferably at 0 to 10 ° C.
- sulfur trioxide or a complex thereof for example, a pyridine complex, a DMF complex, a trimethylamine complex in a non-aqueous solvent at 0 to 100 ° C, preferably at 0 to 10 ° C.
- the cation is exchanged as necessary to obtain the compound of the general formula (VIII).
- a protecting group for an amino group are the same as in the Z wherein formula (VI), ⁇ ⁇ is L i Ding, N a +, K +, R 3 NH ", R 2 NH 2 +, RNH 3 +, Pirijiniumu a monovalent cation such as.
- R represents phenyl, a lower alkyl which may be substituted with Ariru group naphthyl.
- the solvent is 1, 2 Jikuroroetan, black hole Holm, methylene chloride, as tetrahydrofuran, Aprotic solvents such as dioxane, DMF, dimethylacetamide, hexamethylphosphoramide (HMPA), N-methylpyrrolidone and acetonitrile, preferably dimethylformamide (DMF)
- the compound of the general formula (VIII) is a mixture of two diastereoisomers in relation to the asymmetric carbon at the base of the protected amino group due to a new asymmetry at the phosphorus atom. Is added to the above reaction solution Neutralization by adding an aqueous solution of sodium, sodium carbonate, sodium hydrogencarbonate, etc.
- fractionate the chromatographic fraction while confirming the separation by high performance liquid chromatography The separation can be confirmed by monitoring the ultraviolet absorption using, for example, an ODS silica gel column, or using a mixed solution of a buffer or acid aqueous solution and methanol or acetonitrile as an eluent.
- the protecting group Z of the amino group was removed from both stereoisomers of the compound of the general formula (VIII) by a conventional method to produce the compound of the formula (V).
- the method for removing the protecting group varies depending on the protecting group, and each is a known method.
- the benzyloxycarbonyl group must be removed by catalytic reduction, the t-butoxycarbonyl group by acid, the p-methoxybenzyloxycarbonyl group by catalytic reduction or acid, and the phthaloyl group by hydrazinolysis. Can be.
- the compound of the general formula (VIII) having a benzyloxycarbonyl group was later eluted by chromatography using Diaion HP20.
- the substance obtained by removing the benzyloxycarbonyl group by catalytic reduction of the product is characterized by the chromatographic behavior, physicochemical properties, and enzyme inhibitory activity described below. Perfect match with Ostin. Thereby, the synthetic chemical production method of sulfostine of the present invention was achieved.
- n 0 in the general formula (IV), which is a 4-membered ring compound, can be synthesized using a known 4- (carbobenzozoxyamino-1-azetidinone) as it is.
- L-2,4-diaminobutyric acid methyl ester obtained by Hofmann degradation of 2-aminocaprolactam and N-protected glutamine methyl ester can be similarly converted into general formulas (IX), (X), (XI) and Compound (XII) was synthesized.
- n 0, 1 or 3
- Z is the same amino group protecting group as in the general formula (VI)
- M + is the same monovalent cation as in the general formula (VIII).
- room temperature means 10 to 30 ° C.
- Example 1
- the obtained colorless crystals are dissolved in water (1 L), and sodium hydrogen carbonate (11.56 g, 1.4232mo1) is added in several portions under ice-cooling, and the mixture is stirred at room temperature for 15 hours.
- sodium hydrogen carbonate 11.56 g, 1.4232mo1
- a saturated saline solution was added to the reaction solution, and the mixture was separated into an aqueous layer and an organic layer, and the aqueous layer was extracted with a black hole form.
- the organic layer was combined with the separated organic layer, washed with saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off.
- the catalyst in the reaction solution is removed by filtration, and the solvent is concentrated under reduced pressure.
- the residue was purified by Diaion HP-2OSS and recrystallized (water-ethanol) to obtain the desired product (22.0 mg).
- reaction solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate.
- the ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, and the solvent was distilled off.
- reaction solution was separated into an aqueous layer and a black form layer, and the aqueous layer was extracted with black form.
- the chloroform layers were combined, washed with brine, dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was washed with ether to obtain the desired product (2.41 g).
- the catalyst in the reaction solution was removed by filtration, and the solvent was concentrated under reduced pressure.
- the residue was purified by Diaion HP-20S S, and recrystallized (water-ethanol) to obtain the desired product (73.0 mg).
- the sulfostine analog of the present invention can be used as an immunomodulator, a hormone modulator, an anti-HIV drug, an anti-allergic drug, an anti-inflammatory drug, an anti-rheumatic drug and the like. Further, according to the production method of the present invention, sulfostine and its analogs can be produced by synthetic chemical means.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT00925639T ATE246196T1 (de) | 1999-05-17 | 2000-05-12 | Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon |
US10/009,707 US6579989B1 (en) | 1999-05-17 | 2000-05-12 | Sulphostin analogue and process for producing sulphostin and its analogue |
DE60004217T DE60004217T2 (de) | 1999-05-17 | 2000-05-12 | Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon |
EP00925639A EP1184388B1 (en) | 1999-05-17 | 2000-05-12 | Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
CA002372068A CA2372068A1 (en) | 1999-05-17 | 2000-05-12 | Sulphostin analogue and process for producing sulphostin and its analogue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/135854 | 1999-05-17 | ||
JP13585499A JP4121215B2 (ja) | 1999-05-17 | 1999-05-17 | スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000069868A1 true WO2000069868A1 (fr) | 2000-11-23 |
Family
ID=15161335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003055 WO2000069868A1 (fr) | 1999-05-17 | 2000-05-12 | Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues |
Country Status (8)
Country | Link |
---|---|
US (1) | US6579989B1 (ja) |
EP (1) | EP1184388B1 (ja) |
JP (1) | JP4121215B2 (ja) |
AT (1) | ATE246196T1 (ja) |
CA (1) | CA2372068A1 (ja) |
DE (1) | DE60004217T2 (ja) |
ES (1) | ES2199826T3 (ja) |
WO (1) | WO2000069868A1 (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
WO2002055088A1 (fr) * | 2001-01-16 | 2002-07-18 | Nippon Kayaku Kabushiki Kaisha | Remedes destines au traitement de la suppression de la moelle osseuse et de maladies infectieuses et agents permettant d'augmenter la concentration leucocytaire du sang |
WO2004000327A1 (ja) * | 2002-06-24 | 2003-12-31 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | 2型糖尿病治療剤 |
EP1457494A1 (en) * | 2001-12-17 | 2004-09-15 | Nippon Kayaku Kabushiki Kaisha | Processes for preparation of sulphostin and its analogues or intermediates thereof |
US7132443B2 (en) | 2001-06-27 | 2006-11-07 | Smithklinebeecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2007120702A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
JPWO2005027934A1 (ja) * | 2003-09-24 | 2007-11-15 | 日本化薬株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
EP2116235A1 (en) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60322857D1 (de) | 2002-03-25 | 2008-09-25 | Nippon Kayaku Kk | Neues alpha-amino-n-(diaminophosphinyl)lactamderivat |
US7355049B2 (en) * | 2003-06-24 | 2008-04-08 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator |
ATE550656T1 (de) * | 2003-08-20 | 2012-04-15 | Alere San Diego Inc | Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials |
JP4915833B2 (ja) * | 2005-07-01 | 2012-04-11 | 雪印メグミルク株式会社 | ジペプチジルペプチダーゼiv阻害剤 |
CL2007001011A1 (es) | 2006-04-11 | 2008-05-16 | Arena Pharm Inc | Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip. |
JP5148941B2 (ja) * | 2007-07-11 | 2013-02-20 | 公益財団法人微生物化学研究会 | スルフォスチン、及びスルフォスチン関連化合物を有効成分とした抗腫瘍剤 |
JP5916387B2 (ja) | 2009-08-03 | 2016-05-11 | 株式会社カネカ | ジペプチジルペプチダーゼ−4阻害剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1433916A (en) * | 1972-07-13 | 1976-04-28 | Ciba Geigy Ag | Thiophosphoric acid amides as nematocides insecticides and acaricides |
EP0243924A2 (en) * | 1986-04-28 | 1987-11-04 | E.R. Squibb & Sons, Inc. | 2-Oxo-1-(substituted phosphorous)azetidines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH120357A (de) * | 1956-04-05 | 1927-06-01 | Siemens Schuckertwerke Gmbh | Elektromagnetischer Selbstausschalter, insbesondere in Stöpselform. |
US6214340B1 (en) * | 1997-11-18 | 2001-04-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Physiologically active substance sulphostin, process for producing the same, and use thereof |
-
1999
- 1999-05-17 JP JP13585499A patent/JP4121215B2/ja not_active Expired - Fee Related
-
2000
- 2000-05-12 US US10/009,707 patent/US6579989B1/en not_active Expired - Fee Related
- 2000-05-12 DE DE60004217T patent/DE60004217T2/de not_active Expired - Lifetime
- 2000-05-12 EP EP00925639A patent/EP1184388B1/en not_active Expired - Lifetime
- 2000-05-12 AT AT00925639T patent/ATE246196T1/de not_active IP Right Cessation
- 2000-05-12 WO PCT/JP2000/003055 patent/WO2000069868A1/ja active IP Right Grant
- 2000-05-12 CA CA002372068A patent/CA2372068A1/en not_active Abandoned
- 2000-05-12 ES ES00925639T patent/ES2199826T3/es not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1433916A (en) * | 1972-07-13 | 1976-04-28 | Ciba Geigy Ag | Thiophosphoric acid amides as nematocides insecticides and acaricides |
EP0243924A2 (en) * | 1986-04-28 | 1987-11-04 | E.R. Squibb & Sons, Inc. | 2-Oxo-1-(substituted phosphorous)azetidines |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE44186E1 (en) | 2000-03-10 | 2013-04-30 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
WO2002055088A1 (fr) * | 2001-01-16 | 2002-07-18 | Nippon Kayaku Kabushiki Kaisha | Remedes destines au traitement de la suppression de la moelle osseuse et de maladies infectieuses et agents permettant d'augmenter la concentration leucocytaire du sang |
US7247640B2 (en) | 2001-01-16 | 2007-07-24 | Nippon Kayaku Kabushiki Kaisha | Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes |
US7132443B2 (en) | 2001-06-27 | 2006-11-07 | Smithklinebeecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
EP1457494A1 (en) * | 2001-12-17 | 2004-09-15 | Nippon Kayaku Kabushiki Kaisha | Processes for preparation of sulphostin and its analogues or intermediates thereof |
EP1457494A4 (en) * | 2001-12-17 | 2006-04-12 | Nippon Kayaku Kk | PROCESS FOR THE PREPARATION OF SULPHOSTIN AND ITS ANALOGUE OR INTERMEDIATE PRODUCTS THEREOF |
US7531657B2 (en) | 2001-12-17 | 2009-05-12 | Nippon Kayaku Kabushiki Kaisha | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof |
WO2004000327A1 (ja) * | 2002-06-24 | 2003-12-31 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | 2型糖尿病治療剤 |
JP4630192B2 (ja) * | 2003-09-24 | 2011-02-09 | 日本化薬株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
JPWO2005027934A1 (ja) * | 2003-09-24 | 2007-11-15 | 日本化薬株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
JP2011037874A (ja) * | 2003-09-24 | 2011-02-24 | Nippon Kayaku Co Ltd | プロリルオリゴペプチダーゼ阻害剤 |
EP2116235A1 (en) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
WO2007120702A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
EP2253311A2 (en) | 2006-04-11 | 2010-11-24 | Arena Pharmaceuticals, Inc. | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
EP1184388B1 (en) | 2003-07-30 |
ES2199826T3 (es) | 2004-03-01 |
ATE246196T1 (de) | 2003-08-15 |
DE60004217D1 (de) | 2003-09-04 |
JP2000327689A (ja) | 2000-11-28 |
DE60004217T2 (de) | 2004-06-03 |
CA2372068A1 (en) | 2000-11-23 |
JP4121215B2 (ja) | 2008-07-23 |
EP1184388A4 (en) | 2002-10-16 |
EP1184388A1 (en) | 2002-03-06 |
US6579989B1 (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000069868A1 (fr) | Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues | |
EP0614360B1 (en) | Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors | |
Kasahara et al. | Asymmetric total synthesis of (+)-negamycin and (-)-3-epinegamycin via enantioselective 1, 3-dipolar cycloaddition | |
JP4171702B2 (ja) | 新規α−アミノ−N−(ジアミノホスフィニル)ラクタム誘導体 | |
US5952327A (en) | Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives process for their preparation and pharmaceutical compositions comprising them | |
NO158740B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-substituerte 2-azetidinonforbindelser. | |
NZ260736A (en) | Fused n-bicyclic ring containing compounds, preparation and pharmaceutical compositions thereof | |
Williams et al. | Asymmetric synthesis of 2, 6-diamino-6-(hydroxymethyl) pimelic acid: assignment of stereochemistry | |
WO1997002256A1 (fr) | Derive depsipeptidique, son procede de production et son nouvel intermediaire | |
EA003856B1 (ru) | Антипикорнавирусные композиции, их получение и применение | |
AU704704B2 (en) | Proline derivatives useful as inhibitors of human leukocyte elastase | |
JPH02218663A (ja) | 新規なプロリン誘導体 | |
JPH05505820A (ja) | 新規化合物 | |
JP2003521530A (ja) | N−〔(s)−1−カルボキシブチル〕−(s)−アラニンエステルの新規合成方法及びペリンドプリルの合成における適用 | |
CN115768747A (zh) | (2s,5r)-5-(2-氯苯基)-1-(2′-甲氧基-[1,1′-联苯基]-4-羰基)吡咯烷-2-羧酸的合成 | |
JPH0560479B2 (ja) | ||
KR890000769B1 (ko) | 프롤린 유도체의 제법 | |
PT97281A (pt) | Processo para a preparacao de novos derivados contendo fosforo | |
RU2304583C1 (ru) | Способ синтеза ди- и триаминохлоринов | |
JPH0529348B2 (ja) | ||
WO2004099136A1 (ja) | ピロリジン誘導体の製造方法 | |
CN116574154A (zh) | 一种环肽-来那度胺类protac衍生物及其制备方法和在抗癌药物中的应用 | |
TW585853B (en) | Novel tripeptide compounds as inhibitors of trypsin-like serine proteases, process for preparation and pharmaceutical composition thereof | |
JPH08283289A (ja) | ペプチド誘導体の製造方法 | |
AU769718B2 (en) | New processes for producing beta-alanine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2372068 Country of ref document: CA Ref country code: CA Ref document number: 2372068 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000925639 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10009707 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000925639 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000925639 Country of ref document: EP |